Last reviewed · How we verify
Endometriosis
Approved treatments
- Lupron · Accord Healthcare S.L.U.
Leuprolide acetate, a long-acting GnRH analog, initially stimulates then suppresses pituitary gonadotropins, reducing gonadal steroid secretion. - Micronor · Johnson & Johnson
ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects. - Noretynodrel · Pfizer
- Aygestin · Duramed Res
- Synarel · Pfizer
- Depo-Provera · Pfizer
Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy. - Zoladex · Tersera
ZOLADEX inhibits pituitary gonadotropin secretion, leading to regression or inhibition of hormonally sensitive tumors. - Zoladex · Tersera
Zoladex works by mimicking the body's natural hormone to reduce testosterone production. - Lupron · Accord Healthcare S.L.U.
Lupron works by binding to and activating the gonadotropin-releasing hormone receptor, which ultimately leads to a decrease in the production of sex hormones. - Danzol
- Menstridyl
Menstridyl works by blocking the action of cortisol, a hormone involved in the menstrual cycle. - Endometrin · Ferring
- Orilissa · AbbVie
Orilissa blocks the hormone signals that stimulate the growth of endometrial tissue. - Cyklokapron · Exela Pharma
Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, thereby inhibiting fibrinolysis. - Leuprolide Acetate · Pfizer
Leuprolide acetate is a manufactured version of a hormone that regulates growth and development, used to treat hormone-related conditions. - Norinyl 1+50 28-Day
- Eligard · Astellas Pharma Europe Ltd.
- Progesteron · Minia University
- Zoladex · University of Michigan Rogel Cancer Center
- Amchafibrin · Fundación Pública Andaluza Progreso y Salud
- transamin · Erzincan Military Hospital
- Orilissa · University of Wisconsin, Madison
Pipeline
- NORETHINDRONE — Phase 3
Clinical guidelines
- FDA label — 1L
LUPRON DEPOT 3.75 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. It can also be used in combination with norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: